Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate/indacaterol - Novartis

Drug Profile

Glycopyrrolate/indacaterol - Novartis

Alternative Names: Indacaterol maleate/glycopyrronium bromide; Indacaterol/glycopyrrolate; Indacaterol/NVA-237; NVA-237/indacaterol; NVA-237/QAB-149; QVA-149; Ultibro Breezhaler; Ultibro Inhalation Capsules; UltibroBreezhaler; Ulunar Breezhaler; Utibron Neohaler; Xoterna Breezhaler

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arakis Ltd; Novartis; Vectura
  • Developer Novartis; Pfizer; Sunovion Pharmaceuticals
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Indans; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jun 2019 Glycopyrrolate/indacaterol inhalation licensed to Glenmark in Brazil
  • 21 Mar 2019 Launched for Chronic obstructive pulmonary disease in China (Inhalation)
  • 10 Nov 2018 Pooled sub-group analysis efficacy and adverse events data from two phase III FLIGHT 1 and FLIGHT 2 trials in Chronic obstructive pulmonary disease presented at the 91st Annual Scientific Sessions of the American Heart Association (AHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top